We believe that AniGel SR, composed of our Matrix Technology and our proprietary mix of bupivacaine, could be brought to the rapidly expanding $200B+ annual Worldwide Animal Health market in the very near future by the right commercial partner. A few examples of those surgical procedures include:
The combined surgical market for the three segments above represents over 50,000,000 surgeries annually, at a projected ASAP of $75- $100 for Canine and Feline, and $275 for Equine.
In just two years, an estimated 14,000 of the 98,000 veterinarians in the US have been trained on the use of Nocita, an analgesic extending liposome injection. AniGel has soundly outperformed Nocita in head to head tests measuring pain relief and the level of non-toxic pain relief medicine in the bloodstream.
InSitu Biologics intends to pursue a strategic licensing transaction with a worldwide Animal Care Company that it believes could be of significant financial benefit to the Company.
The global pet care market is expected to reach USD 202.6 billion by 2025, according to a new report by Grand View Research, Inc. Rise in the adoption of pets and growing demand for premium care products, and veterinarian care are a few factors expected to drive market growth.
For 2018 reports, find M&A Activity, Capital Market Conditions, and Current Trends for the Pet Industry over at The Deal Hound
According to Wakefield Research, 69% of millennials are likely to use technology to keep track of their pets. InSitu believes that the use of technology for animal healthcare, combined with the early inroads made by Aratana Therapeutics with their sustained release drug, Nocita™, could greatly enhance the value of InSitu’s AniGel BioHydrogel Analgesic Product.
AniGel has repeatedly been proven superior to the Nocita product in 8 different studies, and in three different species.
On June 11, 2019, or CEO Jim Segermark hosted a Q&A webinar with veterinarian Stacie Lipinski. Together they discussed current standards in spay and neuter pain management, as well as the future of sustained-release, regional anesthesia in animals. Additionally, Jim and Stacie reviewed AniGel and the potential market opportunity, as well as answered viewers questions.
Watch the replay here and stay tuned for an update regarding our next Veterinary-focused Q&A webinar in the weeks to come.
Find our study at the Journal of Pain Research titled:
“An evaluation of the analgesic effect of AnestaGel™ on mechanical allodynia in a rat model of postoperative incisional pain”